Eric Lubiner
Hematology & Oncology · North Conway, NHNPI 1487645628
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,510 of the $2,902 with a category attached, or 86.5%. It is spread thinly across 38 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $878 and has fallen 68.2% since, to $279 in 2024. Among hematology & oncology clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $37.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$418
- E.r. Squibb & Sons, L.L.C.$370
- Beigene USA, Inc.$319
- Johnson & Johnson$218
- Bristol Myers Squibb$160
- AstraZeneca$152
- plus $1K from 32 others
What the payments were for
- Speaking & faculty fees$31011%
- Food & beverage$2,51086%
- Education$823%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $418 |
| E.r. Squibb & Sons, L.L.C. | 5 | $370 |
| Beigene USA, Inc. | 5 | $319 |
| Johnson & Johnson | 7 | $218 |
| Bristol Myers Squibb | 3 | $160 |
| AstraZeneca(2 entities) | 3 | $152 |
| Bayer | 2 | $134 |
| Daiichi Sankyo Inc. | 1 | $114 |
| Genmab U.S., Inc. | 1 | $104 |
| Incyte Corporation | 4 | $102 |
| Rigel Pharmaceuticals, Inc. | 1 | $93 |
| Genentech USA, Inc. | 3 | $58 |
| GSK | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Novartis | 2 | $44 |
| Merck | 2 | $40 |
| Seagen Inc. | 2 | $39 |
| Sanofi | 2 | $37 |
| Coherus Oncology, Inc. | 2 | $36 |
| Mirati Therapeutics, Inc. | 1 | $31 |
| Tesaro, Inc. | 1 | $30 |
| Gilead | 2 | $28 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Pfizer | 1 | $22 |
| Exelixis Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $19 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Novocure Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Dova Pharmaceuticals | 1 | $16 |
| Deciphera Pharmaceuticals Inc. | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $14 |
| Taiho Oncology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,902 in reported general payments places this provider in the 90th percentile of 61 hematology & oncology providers in New Hampshire.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 16 | $261,221 |
| Anastrozole | 15 | $360 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in North Conway
- Na LiuNorth Conway$738
- Frederick LansiganLebanon$23K
- Parth ShahLebanon$18K
- Nancy ChunNashua$7K
- Amy BessnowDover$6K
- Konstantin DragnevLebanon$5K
- Keisuke ShiraiLebanon$5K
- David ReismanManchester$2K
- Ivy Riano MonsalveLebanon$2K
- Yoko FukudaPortsmouth$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.